A veterinary medicine specialist based in Cambridge has raised £8m in Series A funding.

PetMedix is applying 30 years of antibody research and the scientific work of two of its founders, Professor Allan Bradley and Dr Jolyon Martin, to develop new pet therapeutics against a wide range of diseases.

The fundraising, led by founder and chief executive Dr Tom Weaver, will be used to establish operations, grow the team, continue to build the platforms, and begin drug discovery.

The investment was led by Digitalis Ventures (NYC) with Parkwalk Advisors (London) as its syndicate partner.

"Digitalis is thrilled to be a part of this journey to bring these innovative therapies to market and excited to work with the talented team that has been assembled at Petmedix," said Cindy Cole, a technical partner with Digitalis Ventures.